27.6 C
New York
Wednesday, June 3, 2026

Tag: institute

newssourceFORcompanyinformationcontent1marketreleases

American Cornerstone Institute to Premiere Star Spangled Adventures: The Movie! at the Trump Kennedy Center

WASHINGTON, June 03, 2026 (GLOBE NEWSWIRE) --

WHAT:
The American Cornerstone Institute (ACI) will host the premiere of Star Spangled Adventures: The Movie!, a new family-friendly film designed to inspire patriotism, faith, and civic understanding in young Americans through storytelling and music.

A2GOLD ANNOUNCES HIGH-GRADE GOLD AND SILVER SURFACE CHANNEL RESULTS FROM BLACKROCK TARGET

CORE DRILLING ONGOING AT CASTLE ZONE (EASTSIDE)TONOPAH, NEV., June 3, 2026 /CNW/ - A2Gold Corp. ("A2Gold" or the "Company") (TSXV: AUAU) (OTCQX: AUXXF) (FRA: RR7)...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

CAHI Honours The Honourable Don Boudria for Leadership in Animal Health

OTTAWA, Ontario, June 02, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to announce the recipients of its 2026 Annual Awards, recognizing exceptional leadership and contributions to Canada’s animal health sector.

Over a million Indian farmers moving to natural farming: APCNF wins the 2026 Food Planet Prize

APCNF (India) wins the $1.5M Food Planet Prize 2026 for leading nearly 2 million Indian farmers through the world's largest agroecology transition.

Toyota’s Collaborative Safety Research Center Touts Partnerships, Eyes Future with Announcement of 10 New Projects

New research projects focus on behavioral safety, crash prevention and passive safetyANN ARBOR, Mich., June 2, 2026 /PRNewswire/ -- Before joining Toyota's Collaborative Safety Research Center (CSRC), Zhaonan Sun spent years...

Looking to the Future from a Space-Based Lab

ISS National Lab highlights space R&D and growing low Earth orbit economy at ASCEND 2026KENNEDY SPACE CENTER, Fla., June 2, 2026 /PRNewswire/ -- The International...

Stardust Power Included in DOE-Funded Lithium Initiative

Stardust Power Included in DOE-Funded Lithium Initiative

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Reshaping PV Value: Sungrow Renewables Launches Smart Module in a Landmark Industry Debut

SHANGHAI, June 2, 2026 /PRNewswire/ -- On June 1, Sungrow Renewables held its 2026 Intelligent Technology Conference in Shanghai. Sungrow Renewables unveiled its new iBuilding...

Manufacturing PMI® at 54%; May 2026 ISM® Manufacturing PMI® Report

New Orders Growing; Production Growing; Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers' Inventories Too Low; Prices Increasing; Imports Growing; Exports GrowingTEMPE,...

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

Jabez Biosciences Announces Opening of Second Clinical Site in Phase 1 study in Solid Tumors and NHL

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInstitute

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers